Price Alert

Avadel Pharmaceuticals (AVDL)

NASDAQ: AVDL · Real-Time Price · USD

13.71

0.21 (1.56%)

At close: Aug 15, 2025, 1:22 PM

Avadel Pharmaceuticals Statistics

Share Statistics

Avadel Pharmaceuticals has 96.89M shares outstanding. The number of shares has increased by 0.65% in one year.

Shares Outstanding	96.89M
Shares Change (YoY)	0.65%
Shares Change (QoQ)	0.27%
Owned by Institutions (%)	79.74%
Shares Floating	80.29M
Failed to Deliver (FTD) Shares	1,933
FTD / Avg. Volume	0.15%

Short Selling Information

The latest short interest is 12.31M, so 12.71% of the outstanding shares have been sold short.

Short Interest	12.31M
Short % of Shares Out	12.71%
Short % of Float	14.84%
Short Ratio (days to cover)	12.68

Valuation Ratios

The PE ratio is -20.48 and the forward PE ratio is 15.72. Avadel Pharmaceuticals's PEG ratio is 0.27.

PE Ratio	-20.48
Forward PE	15.72
PS Ratio	5.91
Forward PS	3.5
PB Ratio	13.54
P/FCF Ratio	-21.32
PEG Ratio	0.27

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Avadel Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.02.

Current Ratio	2.75
Quick Ratio	2.33
Debt / Equity	0.02
Debt / EBITDA	-0.05
Debt / FCF	-0.04
Interest Coverage	-3.91

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$899.56K
Profits Per Employee	$-259.74K
Employee Count	188
Asset Turnover	1.03
Inventory Turnover	0.75

Taxes

Income Tax	-247K
Effective Tax Rate	0.5%

Stock Price Statistics

The stock price has increased by -20.06% in the last 52 weeks. The beta is 1.47, so Avadel Pharmaceuticals's price volatility has been higher than the market average.

Beta	1.47
52-Week Price Change	-20.06%
50-Day Moving Average	10.05
200-Day Moving Average	9.68
Relative Strength Index (RSI)	76.98
Average Volume (20 Days)	1,331,080

Income Statement

In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.

Revenue	169.12M
Gross Profit	153.84M
Operating Income	-42.4M
Net Income	-48.83M
EBITDA	-35.57M
EBIT	-38.25M
Earnings Per Share (EPS)	-0.51

Full Income Statement

Balance Sheet

The company has 51.37M in cash and 1.7M in debt, giving a net cash position of 49.67M.

Cash & Cash Equivalents	51.37M
Total Debt	1.7M
Net Cash	49.67M
Retained Earnings	-794.33M
Total Assets	167.95M
Working Capital	88.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -46.91M and capital expenditures 0, giving a free cash flow of -46.91M.

Operating Cash Flow	-46.91M
Capital Expenditures	n/a
Free Cash Flow	-46.91M
FCF Per Share	-0.49

Full Cash Flow Statement

Margins

Gross margin is 90.97%, with operating and profit margins of -25.07% and -28.87%.

Gross Margin	90.97%
Operating Margin	-25.07%
Pretax Margin	-29.02%
Profit Margin	-28.87%
EBITDA Margin	-21.03%
EBIT Margin	-25.07%
FCF Margin	-27.74%

Dividends & Yields

AVDL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AVDL is $16.5, which is 29% higher than the current price. The consensus rating is "Buy".

Price Target	$16.5
Price Target Difference	29%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.7
Piotroski F-Score	3